Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 7/20 | 1.00 |
| ▸ | DDB1 | Q16531 | 3/20 | 0.86 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.55 |
| ▸ | RAB9A | P51151 | 10/20 | 0.52 |
| ▸ | NPC1 | O15118 | 8/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.52 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 2/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.49 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | TP53 | P04637 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30242926 | 1.00 | CRBN (1.00) | CRBNDDB1NPY5RRAB9ANPC1 | |
| SCHEMBL23067574 | 0.93 | CRBN (1.00) | CRBNDDB1NPY5RRAB9ANPC1 | |
| SCHEMBL30242825 | 0.82 | CRBN (1.00) | CRBNDDB1 | |
| SCHEMBL21496499 | 0.82 | CRBN (0.69) | CRBNDDB1 | |
| SCHEMBL21484140 | 0.82 | CRBN (1.00) | CRBNDDB1 | |
| SCHEMBL21484137 | 0.80 | CRBN (1.00) | CRBNDDB1NPY5RRAB9ANPC1 | |
| SCHEMBL23067560 | 0.76 | CRBN (1.00) | CRBNDDB1NPY5RRAB9ANPC1 | |
| SCHEMBL715696 | 0.76 | RAB9A (0.63) | CRBNDDB1NPY5RRAB9ANPC1 | |
| SCHEMBL23067569 | 0.75 | CRBN (1.00) | CRBNDDB1 | |
| SCHEMBL23075923 | 0.75 | CRBN (0.64) | CRBNDDB1NPC1SMN1; SMN2TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3556760-A1 | SPIRO COMPOUNDS | F. Hoffmann-La Roche AG (CH) | 2019-10-23 | — | — | EP | claimed |
| US-20230416251-A1 | SPIROCYCLIC COMPOUNDS | C4 THERAPEUTICS, INC. (US) | 2023-12-28 | — | — | US | disclosed |
| US-11584748-B2 | Spirocyclic compounds | C4 THERAPEUTICS, INC. (US) | 2023-02-21 | — | — | US | disclosed |
| US-11584748-B2 | Spirocyclic compounds | C4 THERAPEUTICS, INC. (US) | 2023-02-21 | — | — | US | disclosed |
| US-20210032245-A1 | SPIROCYCLIC COMPOUNDS | C4 THERAPEUTICS, INC. (US) | 2021-02-04 | — | — | US | disclosed |
| US-20210032245-A1 | SPIROCYCLIC COMPOUNDS | C4 THERAPEUTICS, INC. (US) | 2021-02-04 | — | — | US | disclosed |
| EP-3556760-A1 | SPIRO COMPOUNDS | F. Hoffmann-La Roche AG (CH) | 2019-10-23 | — | — | EP | disclosed |
| EP-3556760-A1 | SPIRO COMPOUNDS | F. Hoffmann-La Roche AG (CH) | 2019-10-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230416251-A1 | SPIROCYCLIC COMPOUNDS | CRBN, RBX1, XIAP | CRBN 1/4885DDB1 143/4885NPY5R 4841/4885 |
| US-20210032245-A1 | SPIROCYCLIC COMPOUNDS | CRBN, RBX1, XIAP | CRBN 1/4885DDB1 143/4885NPY5R 4841/4885 |
| US-11584748-B2 | Spirocyclic compounds | CRBN, RBX1, XIAP | CRBN 1/4885DDB1 143/4885NPY5R 4841/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.